Last reviewed · How we verify
Corticosteroid: Methylprednisolone
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Multiple sclerosis, Rheumatoid arthritis, Asthma.
At a glance
| Generic name | Corticosteroid: Methylprednisolone |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Methylprednisolone acts as a synthetic glucocorticoid receptor agonist, which leads to anti-inflammatory and immunosuppressive effects.
Approved indications
- Multiple sclerosis
- Rheumatoid arthritis
- Asthma
Common side effects
- Cushing's syndrome
- Adrenal insufficiency
- Osteoporosis
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- OMT for Adhesive Capsulitis (PHASE4)
- Corticosteroid Tapering in Sarcoidosis (NA)
- A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression (PHASE2)
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |